Founded in June 2014, AIDOT’s Cerviray AI is an AI-based remote interpretation system for cervical cancer. Cerviray AI is equipped with AIDOT-NETv1, an AI algorithm developed with AIDOT’s proprietary technology, and the system was developed through joint research with the obstetrics and gynecology departments of two of Korea’s leading hospitals—Seoul National University Bundang Hospital and Korea University Anam Hospital.

Over the past year, AIDOT has pursued joint ventures with large hospitals, screening centers, and multiple companies that provide medical equipment in China, and all of the partner companies concluded that AIDOT’s products are sufficiently ready to enter the Chinese market. AIDOT is now considering various ways to place its products in hospitals directly under health authorities, as well as large secondary and tertiary hospitals and screening centers.

AIDOT established a subsidiary in Beijing in 2017, and in 2020 it established a Korea–China joint venture in Shenzhen. In addition to Cerviray AI, AIDOT also offers the Sonodot AI system based on carotid ultrasound, the Naodot AI system for early stroke diagnosis, and the Gigadot AI system capable of real-time gastroenterology diagnosis. AIDOT is also currently developing an AI system for diagnosing chronic alcoholic liver disease.

Published: November 30, 2021 / NEWSPIM / Reporter Ju Ok-ham